AGPAT4

Across TCGA pan-cancer cohorts, AGPAT4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGPAT4 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AGPAT4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGPAT4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where AGPAT4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.776	1.000	.014	15	view →
PDAC	DFS	Quartile	II,III,IV	0.279	0.603	.009	11	view →
LUAD	DFS	Tertile	II,III,IV	0.446	0.925	.016	10	view →
OV	DFS	Tertile	All	0.758	1.000	.049	8	view →
UCEC	DFS	Median	II,III,IV	0.851	0.550	.045	4	view →
LSCC	DFS	Tertile	II,III,IV	0.518	0.832	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGPAT4–CCRCC (OS)

Open the CCRCC breakdown →